All articles tagged with #abbvie
Genmab’s rinatabart sesutecan (Rina-S) demonstrated a median progression-free survival of 9.5 months in platinum-resistant ovarian cancer, significantly outperforming AbbVie’s Elahere at 5.6 months. While the objective response rate was 45.9%, analysts highlighted superior safety profiles, including no ocular toxicity, and potential for $2 billion in sales.
AbbVie received FDA approval on Friday for tavapadon, branded as Juvmo, the first selective D1/D5 receptor agonist for adults with Parkinson's disease. The approval validates the company's $8.7 billion acquisition of Cerevel Therapeutics, which closed in August 2024. Juvmo is priced at $4,900 per 30-day supply and is expected to launch in the U.S. next month. While the deal's flagship asset, emraclidine, failed in schizophrenia trials in 2025, Juvmo's success provides a new growth avenue for AbbVie's neuroscience division.
AbbVie agreed to acquire Apogee Therapeutics for $10.9 billion in cash, gaining control of zumilokibart, a late-stage anti-IL-13 eczema antibody that could compete with Lilly’s Ebglyss and Regeneron/Sanofi’s Dupixent. The deal complements AbbVie’s immunology portfolio (Skyrizi, Rinvoq) and may offer less frequent dosing (every 3–6 months) based on Phase 2 data. Apogee previously secured up to $1.3 billion from Blackstone Life Sciences, and the transaction values the stock at $135.11 per share. Key milestones include one-year Phase 2 data anticipated in early 2027 and Phase 3 data in 2028."
AbbVie will acquire Apogee Therapeutics for $135.11 per share in cash, valuing Apogee at about $10.9 billion, to broaden AbbVie’s immunology and respiratory portfolio. Apogee’s lead asset zumilokibart (APG777) is an IL-13–targeting monoclonal antibody for atopic dermatitis, with APG273 (a combo with anti-TSLP antibody APG333) in asthma, plus additional antibody programs. The transaction is expected to close in Q3 2026, subject to regulatory and shareholder approvals, and is anticipated to be accretive to AbbVie’s adjusted EPS beginning in 2032. An AbbVie investor conference call is planned for June 22, 2026."
AbbVie is nearing an $11 billion cash deal to acquire Apogee Therapeutics, in what would be its biggest bolt-on in years, paying about $10.9 billion — roughly a 60% premium — for Apogee and its lead inflammatory-disease drug zumilokibart, to bolster AbbVie’s immunology portfolio as Humira faces biosimilar competition.
AbbVie announced a $1.4 billion investment to build a 185-acre pharmaceutical manufacturing campus in Durham, North Carolina, near Research Triangle Park, integrating advanced, AI-enabled manufacturing to support its immunology, neuroscience and oncology medicines. Construction starts in 2026 and is expected to finish by the end of 2028, creating about 734 jobs in manufacturing and laboratory roles, while generating more than 2,000 construction jobs during development. The project represents AbbVie’s largest U.S. capital investment to date and its first major manufacturing footprint in North Carolina, supported by the region’s skilled workforce.
AbbVie announced a $380 million plan to build two new active pharmaceutical ingredient facilities at its North Chicago campus, with construction starting in spring 2026 and full operation expected by 2029. The AI-enabled manufacturing hubs will support next-generation neuroscience and obesity medicines and are part of AbbVie's broader $100 billion U.S. R&D and capital investments commitment, including plans to hire about 300 local workers.
AbbVie and the Trump administration announced a three-year agreement to boost U.S. access and affordability: AbbVie will offer low Medicaid prices, expand direct-to-patient access via the TrumpRx program for medicines including ALPHAGAN, COMBIGAN, HUMIRA and SYNTHROID, and commit $100 billion in U.S.-based R&D and manufacturing investments over the next decade, in exchange for tariff relief and exemption from future price mandates; the deal aims to address all four of the President's drug pricing priorities, with terms kept confidential.
The article highlights three stocks—AbbVie, Coca-Cola, and Realty Income—that are ideal for long-term passive income, emphasizing their strong dividend histories and stability, making them suitable for buy-and-hold investors seeking reliable income streams.
The article highlights three high-yield dividend growth stocks—AbbVie, Home Depot, and ExxonMobil—that offer attractive yields and have a history of increasing their payouts, making them ideal for long-term passive income generation and portfolio diversification.
The article highlights three high-yield dividend growth stocks—AbbVie, Home Depot, and ExxonMobil—that have a strong track record of increasing their dividends for over a decade, making them ideal long-term investments for generating passive income and diversifying a portfolio.
The article highlights three undervalued growth stocks—AbbVie, Lockheed Martin, and PayPal—that offer a combination of low valuation, growth potential, and dividends, making them attractive options for a $5,000 long-term investment.
AbbVie stock surged after securing a patent extension for Rinvoq until April 2037, protecting its revenue from generic competition and supporting its long-term growth prospects, with the drug's sales and potential new indications expected to further boost the company's performance.
AbbVie is acquiring Gilgamesh Pharmaceuticals' investigational drug bretisilocin, a promising psychedelic therapy in Phase 2 trials for major depressive disorder, aiming to expand its psychiatric treatment portfolio. The drug has shown significant antidepressant effects with a shorter psychoactive duration, and the deal includes up to $1.2 billion in potential payments. This move underscores AbbVie's commitment to innovative mental health treatments.
AbbVie announced a $195 million investment to expand its active pharmaceutical ingredient (API) manufacturing capacity in North Chicago, Illinois, as part of a broader plan to invest over $10 billion in the U.S. over the next decade, supporting the production of innovative medicines and creating jobs.